Presentations, Posters & Abstracts

2014 IPCU - Vail, CO

Early Clinical Experience with the 17-Gene Genomic Prostate Score for Newly Diagnosed Prostate Cancer
K Badani, B Denes, AC Tsiatis, M Bonham, T Maddala, G Brown
2014; Poster.

2014 ASCO - Chicago, IL

Abstract #524
Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.
Oleg Gluz et al
2014;

Abstract #6580
Use of the 21-gene recurrence score assay (RS) and chemotherapy (CT) across health care (HC) systems.
Anosheh Afghahi et al
2014;

Abstract #11003
A pilot laboratory study comparing the 21-gene assay and PAM50-ROR.
Che Prasad et al
2014;

Abstract #11024
Recurrence score and quantitative ER expression to predict in late distant recurrence risk in ER+ BC after 5 years of tamoxifen.
Norman Wolmark et al
2014;

Abstract #11052
Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy: Results from PACS01 trial.
Frederique Madeleine Penault-Llorca et al
2014;

Abstract #e22085
In the era of genomics should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?
Xavier B. Pivot et al
2014;

2013 St. Gallen Breast Cancer Conference - St. Gallen, Switzerland

Abstract #P126
Review of traditional prognostic and predictive markers in early-stage breast cancer
Plun-Favreau J, Luthman S, C. Svedman C, et al.
2013;

Abstract #P138
Pooled analysis of 4 European studies assessing the impact of Oncotype DX on treatment decisions
Albanell J, Gligorov J, Holt S.D, et al.
2013;

Abstract #P141
Differences in Recurrence Score (RS) results between luminal A and luminal B breast cancer subtypes
Efrat N., Rizel S, Yerushalmi R, et al.
2013;

Abstract #P145
A comparison of risk classification as assessed by the MammaPrint and Oncotype DX assays
Svedman C, Clough K, Poulet B, et al.
2013;

Abstract #P146
The 21-gene breast cancer assay: summary of clinical evidence
Sing A.P., Baehner F.L., Yoshizawa C, et al.
2013;

Abstract #P147
The Oncotype DX DCIS Score and quantitative gene expression for ER, PR, and HER2: 1,071 patients
Tan V, Bailey H, Tsiatis A, et al.
2013;

Abstract #P148
The development of the DCIS Score: scaling and normalization in the Marin general population
Baehner F.L., Butler S.M., Yoshizawa C, et al.
2013;

Abstract #P154
Oncotype DX VS clinicopathologic factors in breast cancer: the experience from Greece and Cyprus
Nasioulas G, Kesisis G, Razi E, et al.
2013;

Abstract #P156
Impact of the Oncotype DX assay on decision-making in estrogen receptor positive early breast cancer
Jaafar H, Taher A, Quasmeh K, et al.
2013;

Abstract #P19
Quantitative gene expression by RT-PCR in special histologic subtypes of invasive breast cancer
Bailey V, Tsiatas A, Yoshizawa C, et al.
2013;

Abstract #P20
Quantitative gene expression by RT-PCR in classic and variant lobular carcinoma in ER+ breast cancer
Anderson J, Yoshizawa C, Watson D, et al.
2013;

Abstract #P200
Retrospective analysis of treatment decisions in patients with intermediate Recurrence Score results
Fried G
2013;

Abstract #P208
Budget impact analysis of the Oncotype DX Breast Cancer Test in France
Rouzier R, Laas E, Chéreau E, et al.
2013;

Abstract #P213
Recurrence Score fo prognosis and prediction of paclitaxel benefit in node(+)/ER(+) breast cancer
Mamounas E.P, Tang G., Paik S, et al.
2013;

Abstract #P281
Retropspective budget impact analysis on the use of Oncotype DX test in Ireland
Falahee M, Plun-Favreau J, Ercoli K.
2013;

Abstract #P283
Cost-effectiveness analysis of the 21-gene breast cancer test in Mexico
J. Bargallo Rocha F. Lara Medina, R. Shaw Dulin, V. Pérez Sánchez
2013;

Abstract #P284
Cost-effectiveness of Oncotype DX test vs current clinical practice: a Dutch cost perspective
Steuten R, Schutten M, Kip M, et al.
2013;

Abstract #P286
Economic impact of the Oncotype DX results guided adjuvant treatments in Turkey
Rózsa K, Horváth Z, Juhos É, et al.
2013;

Abstract #P287
Using the Recurrence Score in clinical practice: a HMO experience with a unified testing policy
Silverman N, Zick A, Beit-Or A, et al.
2013;

Abstract #P290
Family life during and after breast cancer treatment: A European patient survey
Mimoun D, Elia E, Braybrooke J, et al.
2013;

2013 SABCS - San Antonio, TX

Abstract #P3-05-08
Discordance in hormone receptor (HR) assessment by IHC and RT-PCR in an estrogen receptor (ER) low-positive group (1-10% positive cells): Does accurate assessment of HR status require dual testing?
Singh B, Ziguridis N, Axelrod D, Butler SM, Jamshidian F, Charbavaz DB, Sing AP
2013; 1.

Abstract #P6-05-11
Run-in phase of prospective WSG-ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine
Harbeck N, Gluz O, Kreipe HH, Christgen M, Svedman C, Shak S, Hofmann D, Kuemmel S, Nuding B, Rezai M, Schumacher C, Kusche M, Forstbauer H, Maass N, Kraemer S, Aktas B, Mohrmann S, Wuerstlein R, Kates RE, Nitz U
2013; 1.

Abstract #P6-06-02
Direct comparison of risk classification between MammaPrint®, Oncotype DX® and MammoStrat® assays in patients with early stage breast cancer
Shivers SC, Clark L, Esposito N, Howard N, King J, Acs G, Ellis D, Vrcelj V, Zanchi A, Stork-Sloots L, de Snoo F, Baehner FL, Butler SM, Jamshadian F, Sing AP, Blumencranz PW, Cox CE
2013; 2.

2013 AUA − San Diego, CA

Abstract #2131
Development and validation of the biopsy‐based genomic prostate score (GPS) as a predictor of high grade or extracapsular prostate cancer to improve patient selection for active surveillance
Cooperberg M, Simko J, Falzarano S
2013;

2013 ASCO - GI - San Francisco, CA

Abstract #349
Impact of the recurrence score (RS) result and mismatch repair status (MMR) on agreement between oncologists (MDs) for stage II colon cancer (CC) recurrence risk (RR) assessment: A novel clinical utility endpoint for prognostic markers
Kelley R. K., Lopatin M., Hwang J., et al.
2013;

Abstract #391
Real-world comparative economics of a 12-gene assay for prognosis in stage II colon cancer
Alberts S.R., Yu T., Behrens R.J., et al.
2013;

Abstract #453
Prospective evaluation of a 12-gene assay on treatment recommendations in patients with stage II colon cancer
Srivastava G, Renfro L. A., Behrens R. J.,et al.
2013;

2013 ASCO - Chicago, IL

Abstract #5029
Evidence for a field effect in early prostate cancer (PCa): gene expression profiles in normal‐appearing prostate tissue (NT) adjacent to tumor (T) are predictive of clinical outcome.
Klein E, Maddala T, Lawrence J, Magi-Galluzzi C
2013;

Abstract #3640
Real-world comparative economics of a 12-gene assay for prognosis in stage II colon cancer
Yu T, Alberts S.R., Behrens R. J., et al.
2013;

Abstract #e14569
Impact of the Recurrence Score (RS) result and mismatch repair status (MMR) on agreement between oncologists (MDs) for stage II colon cancer (CC) recurrence risk (RR) assessment: A novel clinical utility endpoint for prognostic markers
Kelley R.K, Lopatin M, Hwang J, et al.
2013;

Abstract #e22111
Association of the colon cancer recurrence score with treatments received in patients with stage II colon cancer: The Clalit Health Services experience
Brenner B, Geva R, Beny A, et al.
2013;

Abstract #11018
Fusion transcript discovery in formalin-fixed paraffin-embedded human breast cancer tissues and its relation to tumor progression
Ma Y, Ambannavar R, Stephans J, et al.
2013;

Abstract #520
The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831
Perez E. A., Butler S. M., Dueck A. C, et al.
2013;

Abstract #560
Ethnic differences in tumor proliferation in women with early-stage breast cancer
Kalinsky K, Lim E.A., Andreopoulou E, et al.
2013;

Abstract #562
Phase II trial evaluating the use of 21-gene recurrence score (RS) to select preoperative therapy in hormone receptor (HR)-positive breast cancer
Zelnak A. B., Murali S, Styblo T. M., et al.
2013;

Abstract #565
Initial results from the 21-gene breast cancer assay registry: A prospective observational study in patients (pts) with ER+, early-stage invasive breast cancer (EBC)
Vacirca J.L, Tsai M. L., Brufsky A, et al.
2013;

Abstract #598
A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer
Kelly C.M., Beamish R, McCaffrey J, et al.
2013;

Abstract #e11531
A retrospective study in the Spanish population with Oncotype dx recurrence score (RS) in breast cancer patients with positive and negative-lymph nodes
Estevez LG, Calvo I, Abad MF, et al.
2013;

Abstract #TPS655
ADAPT: Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer
Harbeck N, Hofmann D, Gluz O, et al.
2013;

2012 SABCS - San Antonio, TX

Abstract #OT3-3-02
ADAPT - Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer
Gluz O, Hofmann D, Kates RE, et al.
2012;

Abstract #P2-10-08
Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the Phase III WSG-planB Trial.
Gluz O, Kreipe HH, Kates RE, et al.
2012;

Abstract #P6-07-03
Risk classification of early stage breast cancer as assessed by MammaPrint and Oncotype DX genomic assays
Poulet B, Jamshidian F, Butler S, et al.
2012;

Abstract #P5-15-01
Cost-effectiveness of gene expression profiling for ductal carcinoma in-situ (Oncotype DCIS Score)
Alvarado MD, Harrison L, Solin LJ, Ozanne EM
2012;

Abstract #P5-15-06
Societal economics of the 21-gene Recurrence Score® in estrogen-receptor-positive early-stage breast cancer in Japan
Yamauchi H, Nakagawa C, Yamashige S, et al.
2012;

Abstract #S1-10
Association Between the 21-Gene Recurrence Score (RS) and Benefit from Adjuvant Paclitaxel in Node-positive, ER-positive Breast Cancer Patients (pts): Results from NSABP B-28
Mamounas EP, Tang G, Paik S, Baehner FL, et al.
2012;

2012 ESMO - Vienna, Austria

Abstract #252
Meta-analysis of prospective European studies assessing the impact of using the 21-gene recurrence score assay on clinical decision making in women with ER-positive, HER2-negative early stage breast cancer
J. Albanell, S. Holt, J. Gligorov, W. Eiermann, C. Svedman
2012;

Abstract #289
Study of the impact of the 21-gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital
J.E.R. Bargallo, F. Lara, R.J. Shaw Dulin, V. Perez-Sánchez, C. Villarreal-Garza, H. Maldonado-Martinez, A. Mohar-Betancourt, C. Yoshizawa, E. Burke, C. Chao
2012;

2012 ASCO Breast Cancer Symposium - San Francisco, CA

Abstract #1
Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28
Mamounas E, Tang G, Paik A, et al.
2012;

Abstract #190
The development of the DCIS score: Scaling and normalization in the Marin General Hospital cohort
Baehner F.
2012;

2012 ASCO - GU - San Francisco, CA

Abstract # 21
Identification of Prostate Cancer-Expressed MicroRNAs Associated with Clinical Recurrence and Prostate Cancer Specific Survival Following Radical Prostatectomy
Klein E, Kiefer M, Crager M, Magi-Galluzzi C, Falzarano S, Pelham R, Cherbavaz D, Baker J, Shak S, Lee M
2012;

2012 ASCO - GI - San Francisco, CA

Abstract #398
Effect of Oncotype DX Colon Cancer Test Results on Treatment Recommendations in Patients with Stage II Colon Cancer: Preliminary Results
Cartwright T, Chao C, Lopatin M, Bentley T, Broder M, Chang E
2012;

2012 ASCO - Chicago, IL.

Abstract #e11002
Evaluation of variables that may impact the use of Oncotype DX testing.
Szabo S, Gilmore J, Haislip S, Hassell R, Cooper J, Richardson S, Fitzgerald M, Feinberg B; Georgia Cancer Specialists PC, Atlanta, GA; Cardinal Health, Specialty Solutions, Dublin, OH; Genomic Health, Redwood City, CA
2012;

Abstract #e11006
Can Oncotype DX recurrence score (RS) be used in luminal A and luminal B breast cancer patients (pts) to predict the likely benefit of chemotherapy? A retrospective study in the Spanish population.
García-Estevez L, Contreras A, Calvo I, Abad M, Cruz J, Perea S, Suárez A, López-Ríos F, Hidalgo M; Centro Integral Oncológico Clara Campal, Madrid, Spain; Centro Médico Guerra Méndez, Valencia, Venezuela; Dpto. Medicina Preventiva y Salúd Pública, UAM, Madrid, Spain
2012;

Abstract #e11032
Evaluation of the Oncotype Dx recurrence score (RS) in hormone-positive ipsilateral breast tumor recurrences.
Wapnir I, Florero M; Stanford University, Stanford, CA
2012;

Abstract #1005
Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study.
Badve S, Gray R, Baehner F, Solin L, Butler S, Yoshizawa C, Shak S, Hughes L, Page D, Sledge G, Davidson N, Perez E, Ingle J, Wood W, Sparano J; Indiana University School of Medicine, Indianapolis, IN; Dana-Farber Cancer Institute, Boston, MA; Genomic Health, Redwood City, CA; Albert Einstein Medical Center, Philadelphia, PA; The Hope Center, Cartersville, GA; Vanderbilt University, Nashville, TN; Indiana University Simon Cancer Center, Indianapolis, IN; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Department of Surgery, Emory University, Atlanta, GA; Albert Einstein College of Medicine, Bronx, NY
2012;

Abstract #1021
10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features.
Sparano J, O'Neill A, Gray R, Perez E, Shulman L, Martino S, Badve S, Baehner F, Childs B, Yoshizawa C, Rowley S, Davidson N, Shak S, Goldstein L; Albert Einstein College of Medicine, Bronx, NY; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Jacksonville, FL; The Angeles Clinic and Research Institute, Santa Monica, CA; Indiana University School of Medicine, Indianapolis, IN; University of California, San Francisco, San Francisco, CA; Sanofi, Bridgewater, NJ; Genomic Health, Redwood City, CA; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Fox Chase Cancer Center, Philadelphia, PA
2012;

Abstract #1525
Cost-effectiveness of the 21-gene recurrence score assay in the setting of multifactorial decision making for chemotherapy in early-stage breast cancer.
Reed S, Dinan M, Schulman K, Lyman G; Duke Clinical Research Institute, Durham, NC; Duke University, Durham, NC
2012;

Abstract #3512
Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox)
O'Connell M, Lee M, Lopatin M, Yothers G, Clark-Langone L, Millward C, Paik S, Sharif S, Shak S, Wolmark N; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Genomic Health, Redwood City, CA; NSABP Biostatistical Center and University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA; National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital, Pittsburgh, PA; National Surgical Adjuvant Breast and Bowel Project and Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA
2012;

Abstract #3626
Effect of the 12-gene colon cancer assay results on treatment recommendations in patients with stage II colon cancer
Cartwright T, Chao C, Lopatin M, Bentley T, Broder M, Chang E; Ocala Oncology, Ocala, FL; Genomic Health, Redwood City, CA; Partnership for Health Analytic Research, LLC, Beverly Hills, CA
2012;

Abstract #549
A prospective clinical utility study of the impact of the 21-gene recurrence score assay (Oncotype DX) in estrogen receptor positive (ER+) node negative (pN0) breast cancer in academic Canadian centers.
Davidson J, Cromwell I, Ellard S, Lohrisch C, Gelmon K, Shenkier T, Villa D, Lim H, Sun S, Taylor S, Taylor M, Czerkawski B, Hayes M, Ionescu D, Pope J, Berube J, Yoshizawa C, Chao C, Peacock S, Chia S; British Columbia Cancer Agency (Fraser Valley Centre), Surrey, BC, Canada; Canadian Centre for Applied Research in Cancer Control, Vancouver, BC, Canada; British Columbia Cancer Agency (Centre for the Southern Interior), Kelowna, BC, Canada; British Columbia Cancer Agency (Vancouver Centre), Vancouver, BC, Canada; Department of Pathology, British Columbia Cancer Agency (Vancouver Centre), Vancouver, BC, Canada; Genomic Health, Redwood City, CA; British Columbia Cancer Research Center, Vancouver, BC, Canada
2012;

Abstract #552
Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial.
Gluz O, Kreipe H, Christgen M, Degenhardt T, Kates R, Liedtke C, Shak S, Clemens M, Salem M, Markmann S, Liedtke B, Aktas B, Henschen S, Pollmanns A, Krabisch P, Uleer C, Augustin D, Thomssen C, Nitz U, Harbeck N; West German Study Group; West German Study Group, Moenchengladbach, Germany; Hannover Medical School, Hannover, Germany; University Hospital Munich, Cologne, Germany; REK Consulting, Otterfing, Germany; University of Muenster, Muenster, Germany; Genomic Health, Redwood City, CA; Klinikum Mutterhaus, Trier, Germany; University Clinics of Cologne, Cologne, Germany; University Clinic of Rostock, Rostock, Germany; Evangelical Hospital, Bergisch Gladbach, Germany; Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany; Johanniter Clinics Stendal, Stendal, Germany; EKO, Oberhausen, Germany; Department of Gynecology and Obstetrics, Klinikum Chemnitz, Chemnitz, Germany; Gynecology Practice, Hildesheim, Germany; Klinikum Deggendorf, Deggendorf, Germany; Martin Luther University Halle, Halle, Germany; West German Study Group and Evangelical Hospital Bethesda, Moenchengladbach, Germany; West German Study Group and University of Munich, Munich, Germany
2012;

Abstract #555
Obesity at diagnosis and breast cancer (BC) recurrence risk based on the 21-gene assay recurrence score (RS).
Ridolfi K, Zhang C, Onitilo A, Ledesma W, Andreason M, Engel K, Kim K, Wisinski K, Tevaarwerk A, Charlson J; Medical College of Wisconsin, Milwaukee, WI; University of Wisconsin Carbone Cancer Center, Madison, WI; Marshfield Clinic, Weston, WI
2012;

Abstract #563
Impact of exogenous female hormone use (EHU) on breast cancer (BC) recurrence as assessed by the 21-gene assay (Oncotype DX).
Ledesma W, Onitilo A, Zhang C, Kim K, Andreason M, Charlson J, Ridolfi K, Engel J, Wisinski K, Millholland R, Dean J, Tevaarwerk A; University of Wisconsin Carbone Cancer Center, Madison, WI; Marshfield Clinic, Weston, WI; Medical College of Wisconsin, Milwaukee, WI; University of Wisconsin Hospital and Clinics Cancer Registries, Madison, WI; University of Wisconsin, Madison, WI
2012;

Abstract #568
Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early-stage breast cancer in France.
Gligorov J, Pivot X, Naman H, Jacot W, Spaeth D, Misset JL, Largillier R, Sautiere JL, Roquancourt A, Pomel C, Rouanet P, Rouzier R, Penault-Llorca F; Francilian Breast Intergroup; APHP Tenon APREC, CancerEst, University Paris VI, Paris, France; University Hospital of Besancon, Besancon, France; Centre Azureen Cancerologie, Mougins, France; Centre Valdorel, Montpellier, France; Centre D'Oncologie De Gentilly, Gentilly, France; Hospital Saint Louis, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU Besançon, Besançon, France; APHP Hôpital Saint-Louis, Paris, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Val d'Aurellle, Montpellier, France; Tenon, Paris, France
2012;

Abstract #569
Evaluation of Oncotype DX testing and subsequent patterns of care in patients (pts) with early-stage breast cancer (ESBC).
Fitzgerald M, Hassell R, Haislip S, Gilmore J, Richardson S, Cooper J, Szabo S, Feinberg B; Cardinal Health, Specialty Solutions, Dublin, OH; Georgia Cancer Specialists PC, Atlanta, GA; Genomic Health, Redwood City, CA
2012;

Abstract #571
Evaluation of variables that may impact chemotherapy (CT) administration after determination of Oncotype DX (ODX) recurrence score (RS).
Bowen K, Gilmore J, Szabo S, Haislip S, Hassell R, Cooper J, Richardson S, Fitzgerald M, Feinberg B; Georgia Cancer Specialists PC, Atlanta, GA; Cardinal Health, Specialty Solutions, Dublin, OH; Genomic Health, Redwood City, CA
2012;

Abstract #6063
Rural versus urban differences among patients (pts) with hormone-receptor positive (HR+) breast cancer (BC) and a 21-gene assay recurrence score (RS).
Andreason M, Zhang C, Onitilo A, Charlson J, Ledesma A, Ridolfi K, Kim K, Wisinski K, Champeny T, Engel J, Millholland R, Dean J, Tevaarwerk A; University of Wisconsin, Madison, WI; Biostatistics, University of Wisconsin, Madison, WI; Marshfield Clinic, Weston, WI; Medical College of Wisconsin, Milwaukee, WI; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Wisconsin Hospital and Clinics Cancer Registries, Madison, WI
2012;

Abstract #6098
Relationship between Oncotype DX testing and the use of chemotherapy in high-risk patients (pts).
Wong W, Cooper J, Richardson S, Feinberg B; CareFirst BlueCross BlueShield, Baltimore, MD; Cardinal Health, Specialty Solutions, Dublin, OH; Genomic Health, Redwood City, CA
2012;

2012 Advances in Genome Biology and Technology Conference - Marco Island, Florida

Abstract #327
Prognostic Biomarker Discovery using RNA-Seq in Two Cohorts of Breast Cancer Patients
D. Sinicropi, M.-L. Liu, J. Stephans, M. Pho, J.Jeong, A. Scott, R. Ambannavar, J. Morlan, R. Pelham, K. Qu, F. Collin, J. Baker
2012;

2011 SABCS - San Antonio, TX

Abstract #OD06-02
Cost-Effectiveness Evaluation of the Oncotype DX Breast Cancer Assay in Clinical Practice in the UK
Holt SDH, Bennett H, Bertelli G, Valentine WJ, Phillips CJ. Prince Philip Hospital, Llanelli, United Kingdom; Cardiff Research Consortium, Cardiff, United Kingdom; Singleton Hospital, Swansea, United Kingdom; Ossian Health Economics and Communications, Basel, Switzerland; Swansea University, Swansea, United Kingdom.
2011;

Abstract #P1-07-11
Consistency and Control in Clinical Assay Technology over Time: The Oncotype DX Recurrence Score and Assessment of Single Gene Expression Levels
Baehner FL, Butler SM, Anderson JM, Ballard J, Tan V, Shak S. Genomic Health, Inc., Redwood City, CA; UCSF, San Francisco, CA.
2011;

Abstract #P1-07-22
A Venezuelan Study of Breast Cancer Estrogen Receptor, Progesterone Receptor and HER2 Receptor Expression by the Standard Method, Immunohistochemistry (IHC), Compared to a New Method, Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Marin C-EM, Ramirez AC, Baehner FL, Yoshizawa C, Acosta MM. Fundacion BADAN, Caracas, Miranda, Venezuela; Genomic Health, Redwood City, CA.
2011;

Abstract #P1-10-04
Cost-Utility of the 21-Gene Breast Cancer Assay (Oncotype DX) in the Irish Healthcare Setting
Lacey L, Chien R, Hornberger J. Lacey Solutions Ltd, South Strand, Skerries, County Dublin, Ireland; Cedar Associates LLC, Menlo Park, CA; Columbia University, New York, NY; Stanford University, Stanford, CA.
2011;

Abstract #P1-10-05
Is the 21-Gene Breast Cancer Test (Oncotype DX) Cost-Effective?
Pronzato P, Plun-Favreau J. Istituto Naz.le Ricerca Cancro, Genova, Italy; Genomic Health International Sàrl, Geneva, Switzerland.
2011;

Abstract #P1-10-06
Economic Analysis of Chemotherapy Costs for Adjuvant Therapy in Breast Cancer in France
Chereau E, Vataire A-L, Laas E, Genin A-S, Aballéa S, Rouzier R. Tenon - APHP, Paris, France; Creativ-Ceutical, Paris, France.
2011;

Abstract #P2-12-26
Impact of the Recurrence Score on Adjuvant Decision-Making in ER-Positive Early Breast Cancer - Results of a Large Prospective Multicentre Decision Impact Study in Node Negative and Node Positive Disease
Rezai M, Eiermann W, Kümmel S, Kühn T, Warm M, Friedrichs K, Schneeweiss A, Markmann S, Eggemann H, Hilfrich J, Jackisch C, Witzel I, Eidtmann H, Kaufmann M, Blohmer JU. Luisenkrankenhaus, Düsseldorf, Germany; Rotkreuzklinikum, München, Germany; Kliniken Essen-Mitte, Essen, Germany; Klinikum Esslingen, Esslingen, Germany; Krankenhaus Holweide, Köln, Germany; Brustzentrum, Hamburg, Germany; Universitätsklinikum, Heidelberg, Germany; Universitätsklinikum, Rostock, Germany; Universitätsklinikum, Magdeburg, Germany; Eilenriedeklinik, Hannover, Germany; Klinikum Offenbach, Offenbach, Germany; Universitätsklinikum Eppendorf, Hamburg, Germany; Universitätsklinikum, Kiel, Germany; Univesitätsklinikum, Frankfurt, Germany; Sankt Gertrauden-Krankenhaus, Berlin, Germany.
2011;

Abstract #P2-12-26
Comparison of Oncotype DX Recurrence Scores between Surgical and Core Biopsy Specimens in Breast Cancer Patients
Stull TS, Goodwin MC, Anderson JM, Baehner FL, Sing AP, Yoshizawa CN, Barrio AV, Frazier TG. The Bryn Mawr Hospital, Bryn Mawr, PA; Genomic Health, Inc, Redwood City, CA.
2011;

Abstract #P4-09-18
Australian Decision Impact Study: The Impact of Oncotype DX Recurrence Score (RS) on Adjuvant Treatment Decisions in Hormone Receptor Positive (HR+), Node Negative (N0) and Node Positive (N+) Early Stage Breast Cancer (ESBC) in the Multidisciplinary Clinic (MDC)
de Boer RH, Baker C, Speakman D, Mann B. Royal Melbourne Hospital, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Peter MacCallum Cancer Institue, Melbourne, Victoria, Australia; Royal Melbourne and Royal Women's Hospital, Melbourne, Victoria, Australia.
2011;

Abstract #P5-13-09
Correlation of Oncotype DX Recurrence Scores with Pathologic Response Following Neoadjuvant Ixabepilone and Cyclophosphamide in Patients with HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial
Yardley DA, Peacock NW, Hendricks C, Huh SY, Ketchum S, Chao C, Yoshizawa C, Burris III HA, Hainsworth JD. Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Center for Cancer and Blood Disorders, Bethesda, MD; Providence Medical Group, Terre Haute, IN; Mercy Hospital, Portland, ME; Genomic Health, Redwood City, CA.
2011;

Abstract #P5-14-03
Genomic Comparison of Paired Primary Breast Carcinomas and Macrometastatic Lymph Node Metastases Using Quantitative RT-PCR by Oncotype DX: Assessment of the Recurrence Score and Quantitative Single Genes
Boolbol SK, Kirstein L, Harshan M, Klein P, Cohen J-M, Chadha M, Baehner FL, Malamud SC. Beth Israel Medical Center, New York, NY; Genomic Health Inc., Redwood City, CA
2011;

Abstract #P5-14-26
Results from a Prospective Clinical Study on the Impact of Oncotype DX on Adjuvant Treatment Decision Making in a Cohort of 142 UK Patients
Holt S, Bertelli G, Brinkworth E, Durrani S, Jones S, Khawaja S, Laggner U, Moe M, Pudney D, Pitcher S, Rolles M, Sharaiha Y, Whelan S. Prince Philip Hospital, Llanelli, Carmarthenshire, United Kingdom; Singleton Hospital, Swansea, West Glamorgan, United Kingdom; Bronglais Hospital, Aberystwyth, Ceredigion, United Kingdom
2011;

Abstract #P5-18-03
First Interim Toxicity Analysis of the Randomized Phase III WSG Plan B Trial Comparing 4xEC-4xDoc Versus 6xTC in Breast Cancer Patients with HER2 Negative Breast Cancer (BC)
Nitz U, Gluz O, Krepe H, Liedtke B, Aktas B, Henschen S, Pollmanns A, Krabisch P, Zuna I, Shak S, Thomsseen C, Harbeck N. West German Study Group, Moenchengladbach, Germany; Breast Centre Niederrhein/Bethesda Hospital, Moenchengladbach, Germany; Bethesda Hospital, Wuppertal, Germany; Medizinishce Hochschule, Hannover, Germany; Evangelical Hospital, Bergisch Gladbach, Germany; University Hospital, Essen, Germany; Johanniter Hospital, Stendal, Germany; Evangelical Hospital, Oberhausen, Germany; City Hospital Chemnitz, Chemnitz, Germany; Genomic Health Inc, Redwood City, Germany; University Hospital Halle/Saale, Halle/Saale, Germany; University Hospital Cologne, Cologne, Germany.
2011;

Abstract #PD03-09
Breast Cancer Recurrence Risk Probed by Whole Transcriptome Next Generation Sequencing in 136 Patients
Baker J, Liu M-L, Crager M, Stephans J, Pho M, Jeong J, Scott A, Ambannavar R, Morlan J, Pelham R, Qu K, Mena RR, Esteban J, Collin F, Sinicropi D. Genomic Health Inc., Redwood City, CA; Providence St. Joseph Medical Center, Burbank, CA.
2011;

Abstract #S4-06
A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): A prospective validation study of the DCIS score from ECOG E5194
Solin LJ, Gray R, Baehner FL, Butler S, Badve S, Yoshizawa C, Shak S, Hughes L, Sledge G, Davidson N, Perez EA, Ingle J, Sparano JA, Wood W. Albert Einstein Medical Center, Philadelphia, PA; Eastern Cooperative Oncology Group, Boston, MA; Genomic Health, Inc., Redwood City, CA; Indiana University, Indianapolis, IN; The Hope Center, Cartersville, GA; University of Pittsburgh, Pittsburgh, PA; Mayo Clinic Jacksonville, Jacksonville, FL; Mayo Clinic Rochester, Rochester, MN; Albert Einstein College of Medicine, Bronx, NY; Emory University, Atlanta, GA.
2011;

Abstract #S4-3
Prospective comparison of risk assessment tools in early breast cancer (recurrence score, uPA/PAI-1, central grade, and luminal subtypes): Final correlation analysis from the phase III WSG-Plan B trial
Gluz O, Kreipe H, Degenhardt T, Kates R, Christgen M, Liedtke C, Shak S, Clemens M, Markmann S, Uleer C, Augustin D, Thomssen C, Nitz U, Harbeck N. West German Study Group, Moenchengladbach, Germany; Medizinische Hochschule, Hannover, Germany; University of Muenster, Muenster, Germany; Genomic Health Inc, Redwood City; Klinikum Mutterhaus, Trier, Germany; Klinikum Suedstadt, Rostock, Germany; Gynecology Practice, Hildesheim, Germany; Klinikum Deggendorf, Deggendorf, Germany; University of Halle/Saale, Halle/Saale, Germany; Bethesda Clinics, Moenchengladbach, Germany; University of Cologne, Cologne, Germany.
2011;

2011 AACR Annual Meeting - Orlando, Florida

Transcriptome Profiling from Formalin-Fixed, Paraffin-Embedded Tumor Specimens by RNA-Seq
Kunbin Qu*, John Morlan, Jim Stephans, Xitong Li, Joffre Baker, Dominick Sinicropi
2010; From Beyond the Genome: The true gene count, human evolution and disease genomics:Boston, MA, USA. 11-13 October 2010.

2010 Society for Urologic Oncology (SUO) Annual Meeting - Bethesda, Maryland

Poster Session
Identification of Genes Associated with Clinical Recurrence in Men with Localized Prostate Cancer Treated with Radical Prostatectomy
Klein E,1Maddala T,2Falzarano S,3Cherbavaz D,2Novotny W,2Millward C,2Magi-Galluzzi C11Cleveland Clinic, Cleveland OH; 2Genomic Health, Inc., Redwood City, CA.
2010;

2010 SABCS - San Antonio, TX.

Abstract #S4-9
Comparing the prediction of chemotherapy benefit in patients with node-negative, ER-positive breast cancer using the recurrence score and a new measure that integrates clinical and pathologic factors with the recurrence score
Tang G, Costantino JP, Crager M, Shak S, Wolmark N. NSABP, Pittsburgh, PA, Genomic Health Inc., Redwood City, CA.
2010;

Abstract #P2-09-06
Meta-Analysis of the Decision Impact of the 21-Gene Breast Cancer Recurrence Score in Clinical Practice
Hornberger J, Chien R. Stanford University, CA; Cedar Associates LLC, Menlo Park, CA.
2010;

Abstract #P3-10-01
Quantitative Gene Expression Analysis in a Large Cohort of Estrogen-Receptor Positive Breast Cancers: Characterization of the Tumor Profiles in Younger Patients (<= 40 yrs) and in Older Patients (>= 70 yrs)
Shak S, Baehner FL, Stein M, Chen I, Yoshizawa C, Watson D, Swain SM. Genomic Health, Inc, Redwood City, CA; Young Survival Coalition, New York, NY; Washington Hospital Center, Washington DC.
2010;

Abstract #P3-10-12
Pilot Phase of the Randomized PlanB Trial: Prospective Comparison of Molecular Classification, Oncotype DX® and Clinical-Pathological Characteristics in Hormone-Receptor (HR) Positive Primary Breast Cancer
Gluz O, Kreipe H, Christgen M, Salem M, Clemens M, Markmann S, Liedtke B, Barinoff J, Aktas B, Henschen S, Lübbe K, Shak S, Baehner R, Liedtke C, Nitz U, Harbeck N, on Behalf of the WSG/AGO Plan B Investigators. West German Study Group/Bethesda Wuppertal, Moenchengladbach, Germany; University of Hannover, Germany; University of Cologne, Dept. OB&GYN, Breast Centre, Germany; Klinikum Mutterhaus der Borromaeerinnen, Trier, Germany; University Hospital Rostock, Germany; Ev. Hospital, Bergisch Gladbach, Germany; Dr. Horst-Schmidt Hospital, Wiesbaden, Germany; University Hospital Essen, Germany; Johanniter Hospital, Stendal, Germany; University Hospital Muenster, Germany; Hospital Henriettenstiftung, Dept. OB&GYN, Hannover, Germany; Breast Center Niederrhein, Bethesda Hospital, Moenchengladbach, Germany; Genomic Health, Inc., Redwood City.
2010;

Abstract #P3-10-13
Prognostic Value of Genomic Analysis after Neoadjuvant Chemotherapy for Breast Cancer
Mayer EL, Shak S, Miller K, Rugo H, Carey L, Ryabin N, Pomeroy C, Yoshizawa C, Winer EP, Burstein HJ. Dana-Farber Cancer Institute, Boston, MA; Genomic Health, Inc, Redwood City, CA; Indiana University Simon Cancer Center, Indianapolis; University of California San Francisco, Helen Diller Family Comprehensive Cancer Center; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill.
2010;

Abstract #P3-10-15
Quantitative Gene Expression by RT-PCR in Classic and Variant Forms of Lobular Carcinoma in Estrogen Receptor Positive Invasive Breast Cancer
Anderson JM, Yoshizawa C, Winer EP, Watson D, Millward C, Tan V, Shak S, Baehner FL. Genomic Health, Redwood City, CA; Dana-Farber Cancer Institute, Boston, MA; University of California, San Francisco.
2010;

2010 ASCO - Chicago, IL.

Abstract #509
Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach.
G. Tang, J. Cuzick, C. Wale, J. P. Costantino, M. Crager, S. Shak, N. Wolmark, M. Dowsett, J. F. Forbes; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Queen Mary, University of London, London, United Kingdom; Genomic Health, Redwood City, CA; National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital, Pittsburgh, PA; The Royal Marsden Hospital, London, United Kingdom; University of Newcastle, Newcastle-upon-Tyne, United Kingdom

Abstract #511
Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer.
K. S. Albain, W. E. Barlow, S. Shak, G. N. Hortobagyi, D. F. Hayes, for The Breast Cancer Intergroup of North America; Loyola University Medical Center, Maywood, IL; Cancer Research and Biostatistics, Seattle, WA; Genomic Health, Redwood City, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Michigan Medical Center, Ann Arbor, MI

Abstract #6075
The recurrence score and chemotherapy treatment in node-positive, ER+ early-stage breast cancer patients in Israel.
S. Klang, N. Liebermann, S. Rizel, N. Ben-Baruch, S. Merling, L. Soussan-Gutman, R. Bugarini, C. Chao, S. Shak; Clalit Health Services, Tel Aviv, Israel; Rabin Medical Center, Petah Tikva, Israel; Kaplan Medical Center, Rehovot, Israel; Teva Pharmaceutical Industries, Netanya, Israel; Genomic Health, Redwood City, CA

Abstract #e11077
Effect of 21-gene recurrence score results on treatment recommendations in patients age 65 and older with lymph node-positive, estrogen receptor-positive breast cancer.
R. Oratz, C. Chao, S. Skrzypczak, C. Ory, M. Broder; New York University School of Medicine, New York, NY; Genomic Health, Redwood City, CA; Partnership for Health Analytic Research, Beverly Hills, CA

Abstract #4501
Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC).
B. I. Rini, M. Zhou, H. Aydin, P. Elson, T. Maddala, D. Knezevic, L. Parodi, R. M. Bukowski, W. F. Novotny, J. W. Cowens; Cleveland Clinic, Cleveland, OH; Genomic Health, Redwood City, CA; Pfizer, Inc., New York, NY; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Abstract #3503
Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score.
M. J. O'Connell, I. C. Lavery, R. G. Gray, P. Quirke, D. J. Kerr, M. Lopatin, G. A. Yothers, M. Lee, K. Clark-Langone, N. Wolmark; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Cleveland Clinic Foundation, Cleveland, OH; University of Birmingham, Birmingham, United Kingdom; University of Leeds, Leeds, United Kingdom; Sidra Medical and Research Center, Doha, Qatar; Genomic Health, Redwood City, CA; National Surgical Adjuvant Breast and Bowel Project Biostatistical Center and University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA; National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital, Pittsburgh, PA
2010;

Abstract #3097
Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer.
V. Stearns, L. K. Jacobs, T. N. Tsangaris, Z. Cheng, S. Slater, M. J. Fackler, C. Chao, R. Bugarini, E. Gabrielson, N.E. Davidson; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Johns Hopkins School of Medicine, Baltimore, MD; Anne Arundel Medical Center, Annapolis, MD; Genomic Health, Redwood City, CA; University of Pittsburgh Cancer Institute, and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA

2008 ASCO Gastrointestinal Cancers Symposium—Orlando, FL

Abstract #301 : Poster Session
Relationship Between Tumor Gene Expression and Recurrence in Patients with Stage II/III Colon Cancer Treated with Surgery + 5-FU/LV in NSABP C-06: Consistency of Results with Two Other Independent Studies
MJ O'Connell, G Yothers, S Paik, IC Lavery, JW Cowens, KM Clark-Langone, MLopatin, JR Hackett, FL Baehner, N Wolmark

Abstract #302 : Poster Session
Relationship Between Tumor Gene Expression and Recurrence in an Observational Cohort of Patients with Stage II/III Colon Cancer Treated with Surgery Only: Quantitative RT-PCR Assay of 375 Genes in Fixed Paraffin-Embedded (FPE) Tissue
I Lavery, J Hammel, J Cowens, K Clark-Langone, J Hackett, F Baehner, G Yothers, M OConnell, N Wolmark
2008;

2008 ASCO Annual Meeting―Chicago, IL

Abstract #3512
Evaluation of Tumor Gene Expression and K-Ras Mutations in FFPE Tumor Tissue as Predictors of Response to Cetuximab in Metastatic Colorectal Cancer
JB Baker, D Dutta, D Watson, T Maddala, S Shak, EK Rowinsky, L Xu, E Clark, DJ Mauro, S Khambata-Ford

2006 ASCO Annual Meeting―Atlanta, GA

Abstract #3518 : Poster Discussion
Relationship Between Tumor Gene Expression and Recurrence in Stage II/III Colon Cancer: Quantitative RT-PCR Assay of 757 Genes in Fixed Paraffin-Embedded (FPE) Tissue
MJ O’Connell, S Paik, G Yothers, JP Costantino, JW Cowens, KM Clark, J Baker, J Hackett, D Watson, N Wolmark
2006;

2003 ASCO Annual Meeting―Chicago, IL

Abstract #763 : Oral Presentation
Quantitative Gene Expression in Non-Small Cell Lung Cancer from Paraffin-Embedded Tissue Specimens: Predicting Response to Gefitinib, an EGFR Kinase Inhibitor
RB Natale, S Shak, N Aronson, S Averbuch, W Fox, D Luthringer, K Clark, J Baker, M Cronin, DB Agus

2003 AACR Oncogenomics Meeting―Phoenix, AZ

Poster Session
Strategies to Optimize Anti-Receptor Therapies
J Baselga